title: Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapy.
abstract: The accumulation of fibrin/fibrinogen and other coagulation factors in and around solid tumors and metastatic foci has been recognized for a century as an aspect of cancer pathology. On this basis, anticoagulants and fibrinolytic agents have been deployed as adjuvant anticancer therapies, but they have proved clinically useful for only a small proportion of tumors and they only control the functions of the coagulant components. Overuse or long-term application of anticoagulants and fibrinolytic agents often lead to undesirable side-effects. Here, we propose that anticancer drugs that act by different mechanisms can inhibit tumor-associated coagulation, and it may be possible to develop drugs that specifically targeting tumor-related coagulation, have specific cytotoxic effects on tumor and metastatic cells. We provide laboratory and clinical evidence supporting the hypothesis and offer proposals for future applications.
authors.affiliation: School of Life Sciences, Department of Bioengineering, Shanghai University, 99 Shangda Rd., Shanghai 200444, China. ludayong@sh163.net
authors.forename: Da Yong
authors.initials: DY
authors.lastname: Lu
authors.forename: Xue Liang
authors.initials: XL
authors.lastname: Chen
authors.forename: Jian
authors.initials: J
authors.lastname: Ding
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods*; D015195:Drug Design; D005340:Fibrinogen / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D008954:Models, Biological; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D005340:Fibrinogen